About UNLOXCYT™ (cosibelimab-ipdl)UNLOXCYT is a human immunoglobulin G1 monoclonal antibody that binds PD-L1 and blocks the interaction between PD-L1 and its T cell receptors, PD-1 and B7.1. This ...

PD-L1 × TIGIT × LAG3 format enables simultaneous interrogation of three complementary checkpoint pathways within a single in vivo system ...

Adding a second checkpoint inhibitor to chemotherapy improves outcomes among patients with non–small cell lung cancer (NSCLC) who have STK11 and/or KEAP1 mutations, according to the authors of a new ...

We evaluated first-line treatment of metastatic microsatellite-stable colorectal cancer with short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade. Patients were ...

Second-line systematic strategy options for the progression of lenvatinib plus tislelizumab treating unresectable hepatocellular carcinoma: A retrospective study. Transarterial chemoembolization ...

Multiple clinical trials targeting the gut microbiome are being conducted to optimize treatment outcomes for immune checkpoint blockade (ICB). To improve the success of these interventions, ...

Pilatus Biosciences Announces First Patient Dosed in Phase 1 Trial of First-in-Class Metabolic Checkpoint Antibody PLT012 in Solid Tumors - First-in-human study underway evaluating anti-CD36 ...

Timing of irAE and survival in NSCLC. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.

January is beginning to heat up, and it is the start of a huge year for Microsoft and Xbox. Next week kicks things off with a Developer Direct on January 22nd, where we will get a deep dive into at ...